Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Head and Neck Neoplasms × bempegaldesleukin × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Head and Neck Neoplasms 1

Interventions

pembrolizumab 4 Cisplatin 4 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Paclitaxel 2 Fluorouracil 2 Docetaxel 2 ponatinib 1 bempegaldesleukin 1 alovudine 1 Thioctic Acid 1 Sonazoid 1 Radiation 1 Pilocarpine 1 Gemcitabine 1 Fluconazole 1 Exercise 1 Carboplatin 1 Amoxicillin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Nektar Therapeutics

Phase 2/3 Terminated

1 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡